Researchers from The University of Texas MD Anderson Cancer Center have developed a first-in-class antibody that targets a protein overexpressed in many cancer types, allowing for the creation of a new radio-theranostic treatment ...
Apr 1, 2026
0
4
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data ...
Sep 7, 2025
0
22
A computational approach by St. Jude Children's Research Hospital scientists promises to make designing T-cell-based immunotherapies that target two cancer-related antigens at the same time far easier and faster.
Aug 13, 2025
0
26
Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led ...
Jul 10, 2025
0
17
Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author ...
Jan 9, 2025
0
13
The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) has shown clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase ...
Sep 7, 2024
0
42
Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its potential against pediatric ...
Aug 5, 2024
0
42
Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors—an advance ...
May 8, 2024
0
68
A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy ...
Jan 18, 2024
0
29
Epigenetic changes can cause prostate cancer to resist treatment by switching genes on or off. One epigenetic mechanism tags genes with DNA methylation marks. This process is mediated by molecules called DNA methyltransferases. ...
Nov 15, 2023
0
37
